scispace - formally typeset
E

Edward D. Lamperti

Researcher at Harvard University

Publications -  21
Citations -  4642

Edward D. Lamperti is an academic researcher from Harvard University. The author has contributed to research in topics: Gene expression & Transgene. The author has an hindex of 15, co-authored 20 publications receiving 4263 citations. Previous affiliations of Edward D. Lamperti include University of Massachusetts Amherst & Boston Children's Hospital.

Papers
More filters
Journal ArticleDOI

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

TL;DR: The results demonstrate that Tet2 is important for normal myelopoiesis, and suggest that disruption of TET2 enzymatic activity favours myeloid tumorigenesis, which may prove valuable as a diagnostic and prognostic tool to tailor therapies and assess responses to anticancer drugs.
Journal ArticleDOI

Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease.

TL;DR: In this paper, the authors used complementary DNA libraries constructed from peripheral tissues to determine whether the messenger RNA encoding APP in these tissues is identical to that expressed in brain, and identified a second APP mRNA that encodes an additional internal domain with a sequence characteristic of a Kunitz-type serine protease inhibitor.
Journal ArticleDOI

Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice

TL;DR: It is shown that Tet2 is a critical regulator of self-renewal and differentiation of hematopoietic stem cells (HSCs) and has a critical role in regulating the expansion and function of HSCs, presumably by controlling 5hmC levels at genes important for the self-Renewal, proliferation, and differentiation.
Journal ArticleDOI

The A2B adenosine receptor protects against inflammation and excessive vascular adhesion

TL;DR: The A2BAR is identified as a new critical regulator of inflammation and vascular adhesion primarily via signals from hematopoietic cells to the vasculature, focusing attention on the receptor as a therapeutic target.